Media stories about Merrimack Pharmaceuticals (NASDAQ:MACK) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 47.4836739094489 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Wired News – Merrimack Expanded Enrollment in Ongoing Randomized Phase-2 SHERLOC Trial of MM-121 in Non … – Digital Journal (digitaljournal.com)
- Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 – Nasdaq (nasdaq.com)
- Merrimack Provides Business Update and Reports 2017 Financial Results – PR Newswire (press release) (prnewswire.com)
- BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer (reuters.com)
- Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer (finance.yahoo.com)
Shares of Merrimack Pharmaceuticals (MACK) traded up $0.06 during mid-day trading on Wednesday, hitting $10.28. The stock had a trading volume of 160,629 shares, compared to its average volume of 130,245. The company has a current ratio of 3.35, a quick ratio of 3.35 and a debt-to-equity ratio of 0.45. The company has a market cap of $138.63, a PE ratio of 0.29 and a beta of 1.59. Merrimack Pharmaceuticals has a one year low of $9.68 and a one year high of $39.90.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-merrimack-pharmaceuticals-mack-stock-price/2030132.html.
Merrimack Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.
Receive News & Ratings for Merrimack Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merrimack Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.